Peritoneal cancer is a rare cancer that starts in the thin tissue lining the abdomen. Symptoms often appear late and can include abdominal pain, swelling, and feeling full quickly after eating.

Zejula can now be used as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk after ...

Elahere is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to a cancer medicine. Elahere is used to treat a type ...

Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...

First Breakthrough Therapy Designation for Daiichi Sankyo and Merck’s raludotatug deruxtecan based on phase 1 trial and REJOICE-Ovarian01 phase 2/3 trial Second Breakthrough Therapy Designation since ...

The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with ...

Effect of nilotinib on cell proliferation and migration of ovarian cancer cells alone and in combination with standard chemotherapy. Background: Advances in laparoscopic surgery have allowed a ...

Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum Patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

The preferred neoadjuvant chemotherapy regimen is a platinum-taxane doublet. The American Society of Clinical Oncology (ASCO) has updated its guidelines on neoadjuvant chemotherapy use in patients ...